Regel Therapeutics

Regel’s T3 platform combines an inactivated CRISPR system, which targets the epigenome without editing or disrupting DNA, with proprietary regulatory elements that restrict interventions to specific cells. This approach can effectively and permanently restore normal gene expression in cells affected by disease. Backed by years of discovery and innovation, Regel’s method is now poised to become a first-in-class therapeutic intervention, transforming the lives of patients with severe and life-threatening genetic disorders.